Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

（2）浆母细胞性淋巴瘤（PBL）：BL由较小的淋巴样细胞组成，PBL不表达B细胞标记物（CD19、CD20、PAX5），表达浆细胞标记物（MUM1、CD38、CD138）和CD56 [4] ...

Flow cytometry showed monoclonal plasma cells positive for CD38, CD138, CD81, CD28, with κ-light chain restriction (figure 5). These cells were negative for CD19, CD20, CD27 and CD117. Serological ...

该群细胞表达： cKappa,CD38,CD138,CD56,CD81dim,CD27dim,CD28dim分化抗原，表达少量的，基本不表达cLambda,CD19,CD20.HLA-DR,CD117,CD33.CD43分化抗原。 图10 免疫分型 ...

This important study shows that soluble uric acid is an endogenous inhibitor of CD38, a regulator of inflammatory responses. The convincing evidence draws both on biochemical analyses and in vivo ...

The Phase I multi-centre and open-label study is structured in two parts. It is anticipated to enrol around 100 subjects with advanced cluster of differentiation 138 (CD138)-expressing cancers. It ...